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L. Henry Edmunds, Jr., MD, Philadelphia, Pa. 
H eparin-induced thrombocytopenia and thrombo- 
sis (HITT) is an increasingly serious risk of 
cardiac surgery and one that may cause multiple 
amputations, stroke, death, and lawsuits. HITT 
causes thrombocytopenia and also the propensity to 
produce "white clots" consisting mainly of platelets 
and fibrin in small and medium-sized arteries rather 
than veins.!' 2The disease, HITT, must be differen- 
tiated from heparin-induced thrombocytopenia 
without hrombosis (HIT), which is usually defined 
as a 40% to 50% decrease in platelet count in 
response to heparin in the absence of another 
explanation.a, 4 Plasma from patients with HIT and 
HITT is abnormal and contains a substance that 
often causes platelet aggregation or serotonin re- 
lease from normal donor platelets when heparin is 
added. 4-12 Both HIT and HITT are unrelated to the 
brief (<2 hours), usually small, decrease in platelet 
count that occurs directly after injection of some 
heparin preparations. 2' 4,13 This transient thrombo- 
cytopenia is a direct effect of heparin on platelet 
sensitivity to soluble agonists and produces momen- 
tary aggregation and sequestration without conse- 
quences. 
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HIT and HITT may or may not be different 
manifestations of the same disease and may or may 
not be partially immunogenic in origin. 4-1~ 15 
These issues are not yet settled, nor is the mecha- 
nism of the disease understood. 4-1~ 14 HIT usually 
develops 5 to 8 days after heparin injection in 3% to 
5% of all patients and causes a sharp, profound 
decrease in platelet count to 50% of preheparin 
values or less. a' 4, 15 Laboratory tests may' confirm 
the diagnosis; sensitivity of the test varies and con- 
tinues robe an issue. 4' 6, la, 15-17 The risk of HIT after 
cardiac operations i bleeding, not thrombosis, and 
the treatment is stoppage of all heparin, 1-4'15' 17 
including that in flushes and "locks. ''18 Platelet 
counts return to the normal range within about 5 
days.a. 4. 14 
For many patients absolutely no clues exist before 
the operation that HITT will develop. Laboratory 
tests before heparin is given do not detect either 
HITT or HIT. a' 4, 17 No test that predicts the throm- 
botic complications of HITT is available. 4 Although 
unusual, devastating complications have developed 
within 2 or 3 days of the first heparin dose and 
within hours after a second dose)' 4 However, two 
warning signs should be sought in all patients before 
cardiac operations: (1) a fall in platelet count to less 
than 50% of preheparin counts (i.e., HIT) 1' 3, 4, 15, 17 
and (2) any past or present venous or arterial 
thromboembolic complication associated with hep- 
arin administration. 3'4 In those patients who have 
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had prior heparin exposure, laboratory tests may 
confirm the diagnosis. 3 4 6, 12, 15-17 Until better tests 
are developed, it is not rational to screen every 
patient because no test predicts HITT. The patient 
described by Riess and colleagues, in this issue of 
the JOURNAL (see page 265), had both warning signs 
and also had a confirming, positive result from a 
platelet response test; they alertly heeded the red 
flags and avoided isaster. 
When the possibility of the disease is known 
before the operation, several strategies have been 
used successfully to avoid HITT. The prostacyclin 
analog iloprost (Berlex Laboratories, Inc. Wayne, 
N.L) works when used with large infusions of phe- 
nylephrine, 19but unfortunately i oprost is no longer 
produced. Aggressive plasmapheresis 17 before oper- 
ation can replace most of the patient's abnormal 
plasma proteins with donor plasma. Low-molecular- 
weight heparins generally, but not always, cross- 
react with platelets 6' 17; heparinoids are less likely to 
do SOl 17'20 Aspirin pretreatment has been used 
successfu!lyY None of these protocols are entirely 
satisfactory or safe; r-hirudin is probably a better 
solution, but more experience is needed. 
HITT may follow HIT, but the incidence is not 
known. It is estimated that HITT develops in be- 
tween 0.3% and 0,4% of patients who receive hep- 
9 arin.2, 4, 15, 17 When postoperative platelet counts fall 
below 40% to 50% of preoperative counts, heparin 
should be stopped and signs of HITT sought. If 
myocardial infarction or limb ischemia develops, 
lytic therapy is usually not very effective 3' 17 and is 
potentiallydangerous early after cardiac operations. 
Surgical thromboembolectomy may help some pa- 
tients,l-3, 15, 17 but it often fails because small arter- 
ies are usually involved. 
HITT and other less serious deficiencies of 
heparin may eVentually retire the drflg, but prob- 
ably not soon. The risk of HIT and HITT may be 
sooner controlled by the use of  safe, effective, 
reversible platelet inhibitors to produce "platelet 
anesthesia" during cardiopulmonary bypass. 22 
r-Hirudin, used successfully by Dr. Riess and his 
colleagues, is not an adequate substitute for hep- 
arin for routine cardiopulmonary b pass for sev- 
eral reasons. First, cardiopulmonary b pass and 
cardiac surgery produce a massive thrombotic 
stimulus and, despite doses of heparin that are 
two to three times those used to treat deep vein 
thrombosis, thrombin forms and circulates in ev- 
ery patient. 23' 24 Thrombin is a powerful protease 
that primarily catalyzes the conversion of fibrino- 
gen to fibrin but also initiates many other 9 
tions including activation of Platelets. In simu- 
lated extracorporeal perfusion we demonstrated 
that r-desulfatohirudin (Ki = 23 V M) is not as 
effective as standard heparin in suppressing either 
thrombin formation or fibrinopeptide A produc- 
tion. 25 The probable reason is that r-hirudin ir/- 
hibits thrombin only after it is formed and there- 
fore does not prevent thrombin formation. 
Although heparin works as a catalyst, he second- 
order rate constant for antithrombin III heparin 
and thrombin is nearly identical to that of native 
hirudin with thrombin (Ki = 20 FM). 26' 27 Anti- 
thrombin III-heparin also inhibits factors Xa and 
IXa and thus has the advantage of partially pre- 
venting thrombin formation. Second, there is no 
pharmaceutical ntidote to r-hirudin; that is, 
there is no protamine or platelet factor 4 to 
reverse the anticoagulant effect when it is time to 
close the wound. 
The contribution of Riess and associates i an 
important one but probably should not be extrap- 
olated to routine cardiopulmonary bypass. Studies 
with r-hirudin in the dog or pig 28'29 provide 
testimonial data but do not elucidate the relevant 
biochemical mechanisms that must be known be- 
fore the drug can be considered safe. Before 
jumping on the r-hirudin bandwagon, look before 
you leap. 
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